GlassScriptPhysician profile
Madhavi D Rayapudi
NPI 1215971668
$7,560.20
in general payments reported to CMS, 2019-2025
30 companies · $962 in 2025
The $962 reported for 2025 was more than what 78% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $776 · 2020: $729 · 2021: $1,196 · 2022: $1,292 · 2023: $1,368 · 2024: $1,238 · 2025: $962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,537 · Consulting Fee: $31.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,536.83 |
| Consulting Fee | $31.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,289.30 | 2019-2025 | Dovato, Cabenuva, Rukobia |
| Abbvie INC. | $733.86 | 2019-2025 | |
| Gilead Sciences, INC. | $715.89 | 2019-2025 | |
| Paratek Pharmaceuticals, INC. | $711.91 | 2019-2024 | Nuzyra |
| Cumberland Pharmaceuticals, INC. | $684.26 | 2019-2025 | Vibativ |
| Takeda Pharmaceuticals U.S.A., INC. | $673.17 | 2020-2025 | Cuvitru |
| Insmed, INC. | $594.52 | 2019-2024 | Arikayce |
| Pfizer INC. | $435.39 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $428.93 | 2019-2024 | Dificid, Zerbaxa, Delstrigo |
| La Jolla Pharmaceutical Company | $372.35 | 2021-2025 | Xerava, Zevtera |
| Grifols USA, LLC | $158.10 | 2022-2025 | Xembify, Gamunex-C |
| Melinta Therapeutics, LLC | $127.80 | 2019-2023 | Vabomere, Rezzayo, Kimyrsa |
| Csl Behring | $82.23 | 2020-2025 | Hizentra |
| Organogenesis INC. | $73.11 | 2024-2025 | Affinity |
| Mimedx Group, INC. | $71.95 | 2024-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $57.17 | 2025 | Fetroja |
| Astellas Pharma US INC | $46.60 | 2023-2024 | Cresemba |
| Tetraphase Pharmaceuticals, INC. | $34.15 | 2020-2025 | |
| Adma Biomanufacturing LLC | $31.55 | 2024 | |
| Invivyd INC | $30.54 | 2025 | Pemgarda |
| Allergan, INC. | $25.68 | 2020 | |
| Convatec INC. | $25.55 | 2025 | |
| Philips North America LLC | $24.96 | 2019 | |
| Mayne Pharma Commercial LLC | $23.07 | 2021 | |
| Dynavax Technologies Corporation | $20.84 | 2020 | |
| Advanced Respiratory, INC | $20.60 | 2019 | |
| Ets Wound Care LLC | $19.96 | 2025 | Mirragen Advanced Wound Matrix |
| Romark Laboratories, Lc | $17.88 | 2019 | |
| Access Pro Medical, LLC | $16.84 | 2025 | Matriderm |
| Ferring Pharmaceuticals INC. | $12.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madhavi Rayapudi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.